Buy Tesamorelin Peptide

Reduction of Visceral (Abdominal) Fat: Research has shown that Tesamorelin effectively reduces visceral adipose tissue (VAT) by 15%–20% over 6–12 months in individuals with HIV-associated abdominal fat accumulation.

In clinical studies, patients achieving an ≥8% VAT reduction experienced significant metabolic benefits, including improved triglyceride levels, enhanced adiponectin levels, and better glucose homeostasis. These changes were sustained over 52 weeks, highlighting tesamorelin’s dual role in reducing harmful abdominal fat and improving endocrine and metabolic health in patients with central fat accumulation [1].

Improved Lipid Profile: Research indicates that Tesamorelin improves lipid profiles by reducing the quantity of visceral adipose tissue (VAT) and enhancing fat quality. Studies in HIV patients with central adiposity showed that tesamorelin decreased VAT volume by 15.2%, leading to reduced cardiovascular risk [2].

Additionally, it increased VAT and subcutaneous fat density (measured in Hounsfield Units), indicating smaller, healthier fat cells. This dual effect, reducing the amount of harmful fat while improving the quality of remaining fat, along with improved triglyceride levels (−50 mg/dL) and cholesterol ratios, highlights tesamorelin’s potential to support metabolic health in patients with central fat accumulation [3].

Better Glucose Metabolism:Tesamorelin demonstrates a neutral effect on glucose regulation while offering metabolic benefits [4]. In a 12-week study with type 2 diabetes patients, tesamorelin did not significantly alter insulin sensitivity, fasting glucose, HbA1c, or overall diabetes control.

However, it reduced total cholesterol and non-HDL cholesterol levels, highlighting its positive impact on lipid metabolism [5]. These findings suggest tesamorelin can improve metabolic health without compromising glycemic control, even in individuals with diabetes.

Body Composition Improvements: Research suggests that Tesamorelin improves body composition by reducing visceral adipose tissue (VAT) and enhancing muscle mass and quality. In HIV patients with abdominal obesity, tesamorelin reduced VAT by 15%–20% over 26–52 weeks while preserving subcutaneous fat [6].

It also increased skeletal muscle density and area, particularly in the rectus and psoas muscles, improving muscle quality. These changes, combined with improved body image and lipid profiles, highlight tesamorelin’s potential for enhancing metabolic and physical health [7].

Potential Benefit for Non-Alcoholic Fatty Liver Disease (NAFLD/NASH): Studies have demonstrated that Tesamorelin significantly reduces liver fat and improves markers of non-alcoholic fatty liver disease (NAFLD). In HIV patients with abdominal obesity, tesamorelin reduced hepatic fat fraction (HFF) by 37% over 12 months, with 35% achieving normal HFF levels (<5%) [8].

It also improved liver enzymes (ALT and AST) in patients with elevated baseline levels, particularly in those with significant VAT reduction. These findings highlight tesamorelin’s potential to address NAFLD in HIV patients [9].

Possible Cognitive Benefits: Tesamorelin studies have shown potential cognitive benefits by increasing IGF-1 levels, which are crucial for brain function. In HIV patients with abdominal obesity, tesamorelin reduced waist circumference and showed a trend toward improved neurocognitive performance over six months, though results were not statistically significant. IGF-1 and growth hormone pathways are linked to brain health, suggesting tesamorelin’s potential to mitigate neurocognitive impairment, though further studies are needed to confirm long-term cognitive effects.